The current stock price of PDEX is 43.38 USD. In the past month the price increased by 36.24%. In the past year, price decreased by -12.26%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.14 | 218.16B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.99 | 192.25B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.38 | 137.24B | ||
| SYK | STRYKER CORP | 26.89 | 135.41B | ||
| BDX | BECTON DICKINSON AND CO | 13.93 | 57.34B | ||
| IDXX | IDEXX LABORATORIES INC | 55.84 | 56.23B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.33 | 48.21B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.29 | 38.25B | ||
| RMD | RESMED INC | 25.48 | 36.82B | ||
| DXCM | DEXCOM INC | 36 | 26.12B | ||
| PODD | INSULET CORP | 64.7 | 20.80B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.32 | 18.15B |
Pro-Dex, Inc. engages in the design, development and manufacture of rotary drive surgical and dental instruments. The company is headquartered in Irvine, California and currently employs 181 full-time employees. The firm has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. The company also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. The company has an approximately 25,000 square foot industrial building in Tustin, California (the Franklin Property).
PRO-DEX INC
2361 McGaw Ave
Irvine CALIFORNIA 92614 US
CEO: Richard L. Van Kirk
Employees: 147
Phone: 19497693200
Pro-Dex, Inc. engages in the design, development and manufacture of rotary drive surgical and dental instruments. The company is headquartered in Irvine, California and currently employs 181 full-time employees. The firm has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. The company also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. The company has an approximately 25,000 square foot industrial building in Tustin, California (the Franklin Property).
The current stock price of PDEX is 43.38 USD. The price decreased by -0.42% in the last trading session.
PDEX does not pay a dividend.
PDEX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
PDEX stock is listed on the Nasdaq exchange.
The Revenue of PRO-DEX INC (PDEX) is expected to grow by 4.48% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
PRO-DEX INC (PDEX) has a market capitalization of 141.42M USD. This makes PDEX a Micro Cap stock.
ChartMill assigns a technical rating of 6 / 10 to PDEX. When comparing the yearly performance of all stocks, PDEX is one of the better performing stocks in the market, outperforming 72.62% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to PDEX. While PDEX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months PDEX reported a non-GAAP Earnings per Share(EPS) of 3.19. The EPS increased by 107.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.94% | ||
| ROA | 17.41% | ||
| ROE | 26.96% | ||
| Debt/Equity | 0.21 |
7 analysts have analysed PDEX and the average price target is 57.12 USD. This implies a price increase of 31.67% is expected in the next year compared to the current price of 43.38.
For the next year, analysts expect an EPS growth of -4.43% and a revenue growth 4.48% for PDEX